Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. The company develops ApoTainer, a kit for hematopoietic stem cell transplantation procedures. It has collaborations with the denovoMATRIX group of the Technische Universität Dresden to conduct examinations into the tentative synergy between ApoGraft and denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine; Cell2in Inc. to conduct scientific evaluations combining ApoGraft with Cell2in's identification technology FreSHtracer, which monitors stem cell quality by utilizing a fluorescent dye to characterize their oxidative stress state; and XNK therapeutics to focus on the development of cell-based therapeutics from NK cells. The company was formerly known as Cellect Biomed Ltd. and changed its name to Cellect Biotechnology Ltd. in July 2016. Cellect Biotechnology Ltd. was incorporated in 1986 and is headquartered in Kfar Saba, Israel.
IPO Year: 2016
Exchange: NASDAQ
Website: cellect.co
Fastest customizable press release news feed in the world
Tel Aviv , Oct. 15, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP") (the "Company"), announced today the record date and distribution date for the contingent value rights (the "CVRs") to be distributed in connection with the previously announced strategic merger with privately-held Quoin Pharmaceuticals, Inc., a specialty pharmaceutical company focused on rare and orphan diseases (the "Merger") and the sale of the Company's subsidiary, Cellect Biotherapeutics Ltd., to EnCellX, Inc., a privately held company based in San Diego, CA (the "Share Transfer"). Upon the closings of the Merger and Share Transfer, the Depositary for the Company's American Depositary Shar
Tel Aviv, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced shareholders voted to approve the previously announced strategic merger agreement with privately-held Quoin Pharmaceuticals, a specialty pharmaceutical company focused on rare and orphan diseases, and all other proposals presented at the Special General Meeting of shareholders held on September 26, 2021, including the sale of the Company's subsidiary, Cellect Biotherapeutics Ltd, to EnCellX Inc. , a privately held company based in San Diego, CA. Approximately 99% of the votes cast on the strategic merger agreement at the Special General Meeting voted in favor of approving the proposal. The
Tel Aviv, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Reflecting continued clinical progress, Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced the first ApoGraftTM transplantation in a Leukemia patient in the Company's clinical trial at Washington University in the U.S. ApoGraftTM is a product based on the Company's cell selection technology designed to optimize immune therapy, in this application - prevent graft-versus-host disease (GVHD) following bone marrow transplantation. Following the closing of the previously announced strategic merger transaction between Cellect and Quoin Pharmaceuticals, ApoGraftTM development will be pursued by EnCellX, the privately held U.S. based company that
Strategic Merger Transaction Remains on Track to Close During the 2021 Third Quarter Tel Aviv, Israel, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, today reported financial and operating results for the second quarter ended June 30, 2021, and provided an update on the proposed strategic merger with privately-held Quoin Pharmaceuticals and recent clinical news On August 12, the Securities and Exchange Commission (SEC) declared effective the Company's Form F-4 in connection with the proposed strategic merger with Quoin Pharmaceuticals. Quoin is a s
Special General Meeting of Shareholders Scheduled for September 19, 2021 Tel Aviv, Israel, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, announced that its registration statement filed on Form F-4 with Securities and Exchange Commission ("SEC") on August 10, 2021 was declared effective by the SEC on August 12, 2021 (the "Form F-4"). The Form F-4 was filed in connection with the previously announced strategic merger with Quoin Pharmaceuticals, Inc., a privately held U.S. based company focused on rare and orphan diseases. The Company has scheduled a Special General Mee
Tel Aviv, Israel, June 16, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, announced today that it has filed a registration statement, including a joint proxy statement/prospectus ("Proxy Statement"), with the Securities and Exchange Commission (SEC) in connection with its proposed strategic merger with privately-held Quoin Pharmaceuticals. Quoin is a specialty pharmaceutical company focused on rare and orphan diseases. Quoin's leadership team is made up of industry veterans, with extensive relevant executive experience and proven records of recent success in the pharmaceutical i
Tel Aviv, Israel, April 19, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, today announced positive data from the Company's open label Phase 1/2 clinical trial of its ApoGraft™ technology in Israel. All eleven patients enrolled for the trial were transplanted using the ApoGraft product and were engrafted in a timely manner. The primary objective, safety and tolerability of ApoGraft administered to patients with hemato-oncology disorders, was met and there were no procedure related adverse events (AEs) reported during the course of the study. As previously announced last month
Up to $25 million of funding at $75 million pre-money valuation to be available to the combined company concurrently with the merger Cellect shareholders to retain 25% of the combined Company pre-funding Tel Aviv, Israel and Ashburn, VA , March 24, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology that enables the functional selection of stem cells, and Quoin Pharmaceuticals Inc. (“Quoin”), a privately held specialty pharmaceutical company, today announced that the Boards of Directors of the two companies have unanimously approved a definitive Merger Agreement (the “Agreement”). Under the terms of the Agreement, C
6-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
6-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
6-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
6-K - Cellect Biotechnology Ltd. (0001671502) (Filer)
6-K - Cellect Biotechnology Ltd. (0001671502) (Filer)
6-K - Cellect Biotechnology Ltd. (0001671502) (Filer)
6-K - Cellect Biotechnology Ltd. (0001671502) (Filer)
6-K - Cellect Biotechnology Ltd. (0001671502) (Filer)
6-K - Cellect Biotechnology Ltd. (0001671502) (Filer)
6-K - Cellect Biotechnology Ltd. (0001671502) (Filer)
This live feed shows all institutional transactions in real time.
SC 13G - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)
SC 13G/A - Cellect Biotechnology Ltd. (0001671502) (Subject)